Anti-aging composition and application thereof

Abstract

The invention provides an anti-aging composition. The anti-aging composition comprises sialic acid and equol. According to the composition disclosed by the invention, the sialic acid and the equol are compounded, so that collagen generation can be remarkably promoted, the composition has remarkable effects of resisting aging, removing wrinkles and improving skin elasticity, and compared with single sialic acid and single equol, the composition disclosed by the invention has a synergistic interaction effect.

Description

Technical Field

[0001] The present application belongs to the field of cosmetic technology, and specifically, relates to an anti-aging composition and uses thereof. Background Art

[0002] Collagen loss is one of the most obvious manifestations of skin aging, which can cause skin sagging, loss of elasticity and wrinkles. Therefore, increasing collagen synthesis has become an important way to maintain skin elasticity and delay aging.

[0003] Equol is the main metabolite of soy isoflavones under the action of intestinal microorganisms. Due to its hormone-like activity, it plays an important role in regulating hormone levels. When the body lacks estrogen, it can act as an estrogen agonist; when the estrogen level in the body is too high, equol can act as an antagonist to competitively bind to the estrogen receptor (ER), thereby reducing the risk of diseases caused by excessive estrogen (such as uterine fibroids, breast cancer, ovarian cancer, etc.). At the same time, it can inhibit skin photoaging and delay skin aging.

[0004] Sialic acid (SA) is mainly found in the brain, nerve tissue, blood, mucin, and breast milk of mammals. It can participate in the movement of neurotransmitters, promote the differentiation, development, and regeneration of nerve cells, and help improve infants' memory and cognitive abilities. At the same time, it can inhibit collagen degradation and achieve firming and anti-aging effects. Summary of the invention

[0005] The purpose of the present application is to provide an anti-aging composition and its use.

[0006] Specifically, this application involves the following aspects:

[0007] 1. An anti-aging composition comprising sialic acid and equol,

[0008] The mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5.

[0009] 2. The composition according to item 1, wherein the mass content of sialic acid is 0.0001%-0.3%, and the mass content of equol is 0.0001%-0.3%.

[0010] 3. Use of the composition described in item 1 or 2 in the preparation of products promoting collagen production or anti-aging.

[0011] 4. The use according to item 3, wherein the collagen is type I or type III collagen.

[0012] 5. The use according to item 3 or 4, wherein the product is a cosmetic or a medicine.

[0013] 6. Use of a combination of sialic acid and equol in the preparation of products for promoting collagen production or anti-aging.

[0014] 7. The use according to item 6, wherein the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5.

[0015] 8. The use according to item 6 or 7, wherein the collagen is type I or type III collagen.

[0016] 9. The use according to any one of items 6 to 8, wherein the product is a cosmetic or a medicine.

[0017] The composition of the present application can significantly promote the production of type I and type III collagen by compounding sialic acid and equol, and has significant anti-aging, anti-wrinkle and skin elasticity improving effects. In addition, compared with single sialic acid and equol, the composition of the present application has a synergistic effect. DETAILED DESCRIPTION

[0018] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.

[0019] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are provided for illustration only and are not restrictive. The present application is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present application.

[0020] The present application provides an anti-aging composition, comprising sialic acid and equol.

[0021] In a specific embodiment, in the anti-aging composition, the mass ratio of sialic acid to equol is 1:100-1:0.1, for example, it can be 1:100, 1:99, 1:98, 1:97, 1:96, 1:95, 1:94, 1:93, 1:92, 1:91, 1:90, 1:89, 1:88, 1:87, 1:86, 1:85, 1:84, 1:83, 1:82, 1:81, 1:80, 1:79, 1:78, 1:77, 1:76, 1:75, 1:74, 1:73, 1:72, 1:71, 1:70, 1:69, 1:68, 1:67, 1:66, 1:65, 1:64, 1:63, 1:62, 1:61, 1:60, 1:59, 1:58, 1:57, 1:56, 1:55, 1:54, 1:53, 1:52, 1:51, 1:5 0, 1:49, 1:48, 1:47, 1:46, 1:45, 1:44, 1:43, 1:42, 1:41, 1:40, 1:39, 1:38, 1:37, 1:36, 1:35, 1:34, 1:33, 1:32, 1:31, 1:30, 1:29, 1:28, 1:27, 1:26, 1:25, 1:24, 1:23, 1:22, 1:21, 1:20, 1 :19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1:0.9, 1:0.8, 1:0.7, 1:0.6, 1:0.5, 1:0.4, 1:0.3, 1:0.2, 1:0.1, and any range between these values.

[0022] In a specific embodiment, in the anti-aging composition, the mass ratio of sialic acid to equol is 1:0.5-1:8.

[0023] In a specific embodiment, in the anti-aging composition, the mass ratio of sialic acid to equol is 1:1-1:5.

[0024] In a specific embodiment, in the anti-aging composition, the mass content of sialic acid is 0.0001%-0.3%, for example, it can be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%. 9%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, and Any range between these values; the mass content of equol is 0.0001%-0.3%, for example, it can be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0. 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, and any range between these values.

[0025] In a specific embodiment, in the anti-aging composition, the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5, the mass content of sialic acid is 0.0001%-0.3%, and the mass content of equol is 0.0001%-0.3%.

[0026] Those skilled in the art will appreciate that the anti-aging composition may include only sialic acid and equol, or may further include acceptable excipients. Acceptable excipients may include, for example, solvents (such as butylene glycol), diluents, excipients, buffers, fillers, binders, disintegrants, preservatives, lubricants, odorants, flavoring agents, sweeteners, etc., or other ingredients used in cosmetics.

[0027] In a specific embodiment, the anti-aging composition consists of sialic acid and equol.

[0028] In a specific embodiment, the anti-aging composition is composed of sialic acid and equol. In the anti-aging composition, the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5.

[0029] In a specific embodiment, the anti-aging composition consists of sialic acid, equol and acceptable excipients.

[0030] In a specific embodiment, the anti-aging composition is composed of sialic acid, equol and acceptable excipients. In the anti-aging composition, the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5.

[0031] In a specific embodiment, the anti-aging composition is composed of sialic acid, equol and acceptable excipients. In the anti-aging composition, the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5, the mass content of sialic acid is 0.0001%-0.3%, and the mass content of equol is 0.0001%-0.3%.

[0032] The present application also provides use of any one of the above anti-aging compositions in promoting collagen production or anti-aging.

[0033] The present application also provides use of any one of the above anti-aging compositions in preparing products that promote collagen production or anti-aging.

[0034] In a specific embodiment, the collagen comprises type I or type III collagen.

[0035] In a specific embodiment, the collagen is type I or type III collagen.

[0036] In a specific embodiment, the product is a cosmetic, for example, a face cream, a face mask, an eye cream, a neck cream, a hand cream, a body lotion, a moisturizer, an essence, a toner, a shampoo, a conditioner, a scalp care solution, a shower gel, a facial cleanser, a mouthwash or a toothpaste.

[0037] In a specific embodiment, the product is a pharmaceutical product.

[0038] Those skilled in the art will appreciate that, depending on the type of product, the product may also include various types of acceptable adjuvants. Acceptable adjuvants may include, for example, solvents, diluents, excipients, buffers, fillers, binders, disintegrants, preservatives, lubricants, odorants, flavoring agents, sweeteners, etc.

[0039] The present application also provides use of a combination of sialic acid and equol in promoting collagen production or anti-aging.

[0040] The present application also provides use of a combination of sialic acid and equol in preparing a product for promoting collagen production or anti-aging.

[0041] Among them, those skilled in the art will understand that sialic acid and equol can be administered simultaneously or sequentially.

[0042] In a specific embodiment, the collagen comprises type I or type III collagen.

[0043] In a specific embodiment, the collagen is type I or type III collagen.

[0044] In a specific embodiment, the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:5.

[0045] In a specific embodiment, the product is a cosmetic, for example, a face cream, a face mask, an eye cream, a neck cream, a hand cream, a body lotion, a moisturizer, an essence, a toner, a shampoo, a conditioner, a scalp care solution, a shower gel, a facial cleanser, a mouthwash or a toothpaste.

[0046] In a specific embodiment, the product is a pharmaceutical product.

[0047] Those skilled in the art will appreciate that, depending on the type of product, the product may also include various types of acceptable adjuvants. Acceptable adjuvants may include, for example, solvents, diluents, excipients, buffers, fillers, binders, disintegrants, preservatives, lubricants, odorants, flavoring agents, sweeteners, etc.

[0048] Example

[0049] Example 1

[0050] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.0015%, and the mass content of equol was 0.0015%.

[0051] Example 2

[0052] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.0005% and the mass content of equol was 0.0025%.

[0053] Example 3

[0054] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.00027% and the mass content of equol was 0.00273%.

[0055] Example 4

[0056] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.00019% and the mass content of equol was 0.00281%.

[0057] Example 5

[0058] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.00014% and the mass content of equol was 0.00286%.

[0059] Example 6

[0060] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.00007% and the mass content of equol was 0.00293%.

[0061] Example 7

[0062] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.0025% and the mass content of equol was 0.0005%.

[0063] Example 8

[0064] Sialic acid and equol were dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.00273% and the mass content of equol was 0.00027%.

[0065] Example 9

[0066] Sialic acid and equol are dissolved in 0.1% butanediol, wherein the mass content of sialic acid is 0.003%, and the mass content of equol is 0.003%.

[0067] Comparative Example 1

[0068] Sialic acid was dissolved in 0.1% butanediol, wherein the mass content of sialic acid was 0.003%.

[0069] Comparative Example 2

[0070] Equol was dissolved in 0.1% butylene glycol, wherein the mass content of equol was 0.003%.

[0071] Test example

[0072] The solutions prepared in the above examples and comparative examples were used as sample groups for testing. The negative control group was a sample without any examples or comparative examples, and a 5 J / cm 2 The fibroblasts were irradiated with UVA, and the blank control group was a group in which no sample of any embodiment or comparative example was added and the fibroblasts were cultured normally, that is, without UVA irradiation.

[0073] 1. Inoculate fibroblasts into 6-well plates (3×10 5 / well) and incubated at 37°C, 5% CO2 for 24 h.

[0074] 2. After incubation, remove the culture medium and wash with D-Hanks 1-2 times. The sample group and the negative control group were irradiated with UVA (5J / cm 2 ).

[0075] 3. After modeling, the normal control group and the model control group were replaced with fresh culture medium, and fresh culture medium containing samples was added to the sample wells, and incubated at 37°C, 5% CO2 for 24 hours.

[0076] 4. Extract total RNA from each experimental group, synthesize cDNA, and use q-PCR to detect the gene expression of β-actin and target genes.

[0077] 5. Use β-actin as the internal reference for gene expression and calculate the relative RNA expression of the target gene.

[0078] Relative RNA expression = 2 ΔΔC(t)

[0079] in,

[0080] ΔC(t)=C(t) 目的基因 —C(t) β-actin

[0081] In the above formula Denotes ΔC(t) 模型对照组 The average value of .

[0082] 6. Statistical analysis of results: The comparison between the groups was performed using t-test statistical analysis. All statistical analyses were two-tailed. P<0.05 was considered to be significantly different, and P<0.01 was considered to be extremely significantly different. When the t-test method was used for statistical analysis, the significance of the NC group compared with the BC group was indicated by #, P-value < 0.05 was indicated by #, P-value < 0.01 was indicated by ##, and P-value < 0.001 was indicated by ###; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, P-value < 0.01 was indicated by **, and P-value < 0.001 was indicated by ***. Compared with the monomer and the composite, P-value < 0.05 was indicated by ▲, P-value < 0.01 was indicated by ▲▲, and P-value < 0.001 was indicated by ▲▲▲.

[0083] 7. Experimental results: The test results are shown in Tables 1 and 2.

[0084] Table 1 Sialic acid + equol 1:1 COL I test results

[0085]

[0086] Table 2 Sialic acid + equol 1:1 COL III test results

[0087] Group Relative expression of COLIIIA1 gene Blank control (BC) 3.703 Negative control (NC) 1.006### Example 9 2.700** Comparative Example 1 1.223▲▲ Comparative Example 2 1.210▲▲

[0088] The results showed that compared with the negative control group, the samples obtained in the examples of the present application can significantly promote the expression of type I and type III collagen, and when sialic acid and equol are present in a specific mass ratio, they also have a synergistic effect.

Claims

1. An anti-aging composition comprising sialic acid and equol, The mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:

5.

2. The composition according to claim 1, wherein the mass content of sialic acid is 0.0001%-0.3%, and the mass content of equol is 0.0001%-0.3%.

3. Use of the composition according to claim 1 or 2 in the preparation of products for promoting collagen production or anti-aging. The use according to claim 3 , wherein the collagen is type I or type III collagen.

5. The use according to claim 3 or 4, wherein the product is a cosmetic or a medicine.

6. Use of a combination of sialic acid and equol in the preparation of products for promoting collagen production or anti-aging.

7. The method according to claim 6, wherein the mass ratio of sialic acid to equol is 1:0.5-1:8, preferably 1:1-1:

5.

8. The use according to claim 6 or 7, wherein the collagen is type I or type III collagen.

9. The use according to any one of claims 6 to 8, wherein the product is a cosmetic or a medicine.

Images